P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro

International Journal of Oncology

Volumn 34, Issue 5, 2009, Pages 1303-1312

  Seo, Satoru ^a   Hatano, Etsuro ^a   Higashi, Tatsuya ^b   Nakajima, Akio ^a   Nakamoto, Yuji ^a   Tada, Masaharu ^a   Tamaki, Nobuyuki ^a   Iwaisako, Keiko ^a   Kitamura, Koji ^a   Ikai, Iwao ^a   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shiga Medical Center   (Japan)

Author keywords

18F fluorodeoxyglucose; Glucose transporter; P glycoprotein

Indexed keywords

CEPHARANTHINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLYCOPROTEIN P; HEXOKINASE; HEXOKINASE 2; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION;

CALCIUM CHANNEL BLOCKERS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 2; GLUCOSE-6-PHOSPHATASE; HEXOKINASE; HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 67649445777     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000257     Document Type: Article

References (53)

1. Rocken C and Carl-McGrath S: Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 19: 269-278, 2001.
2. Schwartz JD, Schwartz M, Mandeli J and Sung M: Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3: 593-603, 2002.
3. Borst P, Evers R, Kool M and Winholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302, 2000.
4. Van Veen, HW, Higgins CF and Konings WN: Molecular basis of multidrug transport by ATP-binding cassette transporters: a proposed two-cylinder engine model. J Mol Microbiol Biotechnol 3: 185-192, 2001.
5. Chan HS, Haddad G, Thorner PS, De Boer G, Lin YP, Ondrusek N, Yeger H and Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614, 1991.
6. Cheng AL, Su IJ, Chen YC, Lee TC and Wang CH: Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 11: 109-115, 1993.
7. Okazumi S, Isono K, Enomoto K, et al: Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 33: 333-339, 1992.
8. Shiomi S, Nishiguchi S, Ishizu H, et al: Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96: 1877-1880, 2001.
9. Takeuchi Y, Sugimoto M, Ochiai K and Ito K: Expression of P-glycoprotein in rat hepatocarcinogenesis by diethylnitrosamine and the modulation by anticancer drugs. Hepatol Res 22: 107-118, 2002.
10. Weber G and Cantero A: Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues. Cancer Res 15: 105-108, 1955.
11. Torizuka T, Tamaki N, Inokuma T, et al: In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36: 1811-1817, 1995.
12. Seo S, Hatano E and Higashi T: Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 13: 427-433, 2007.
13. Westergaard N, Brand CL, Lewinsky RH, Andersen HS, Carr RD, Burchell A and Lundgren K: Peroxyvanadium compounds inhibit glucose-6-phosphatase activity and glucagon-stimulated hepatic glucose output in the rat in vivo. Arch Biochem Biophys 366: 55-60, 1999.
14. Shiraga K, Sakaguchi K, Senoh T, et al: Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicin-resistant sublines. J Gastroenterol Hepatol 16: 460-466, 2001.
15. Shen DW, Cardarelli C, Hwang J, et al: Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261: 7762-7770, 1986.
16. Woodland C, Koren G, Wainer IW, Batist G and Ito S: Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. Can J Physiol Pharmacol 81: 800-805, 2003.
17. Rigo P, Paulus P, Kaschten BJ, et al: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23: 1641-1674, 1996.
18. Stokkel MP, ten Broek FW and van Rijl PP: The role of FDG PET in the clinical management of head and neck cancer. Oral Oncol 34: 466-471, 1998.
19. Eary JF and Conrad EU: Positron emission tomography in grading soft tissue sarcomas. Semin Musculoskelet Radiol 3: 135-138, 1999.
20. Minn H, Joensuu H, Ahonen A and Klemi P: Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 61: 1776-1781, 1988.
21. Smith TA, Titley JC and McCready VR: Proliferation is associated with 2-deoxy-D-[1-3H]glucose uptake by T47D breast tumour and SW480 and SW620 colonic tumour cells. Nucl Med Biol 25: 481-485, 1998.
22. Minn H, Clavo AC, Grenman R and Wahl RL: In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 36: 252-258, 1995.
23. Haberkorn U, Ziegler SI, Oberdorfer F, et al: FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 21: 827-834, 1994.
24. Aloj L, Caraco C, Jagoda E, Fckelman WC and Neumann RD: Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 59: 4709-4714, 1999.
25. Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, Larson SM and Fong Y: Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia 3: 189-195, 2001.
26. Higashi T, Tamaki N, Honda T, et al: Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 38: 1337-1344, 1997.
27. Pedersen MW, Holm S, Lund EL, Hojgaard L and Kristjansen PE: Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 3: 80-87, 2001.
28. Brown RS, Goodman TM, Zasadny KR, Greenson JK and Wahl RL: Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 29: 443-453, 2002.
29. Higashi T, Saga T, Nakamoto Y, et al: Relationship between retention index in dual-phase (18) F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 43: 173-180, 2002.
30. Scheepers A, Joost HG and Schurmann A: The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 28: 364-371, 2004.
31. Mueckler M: Facilitative glucose transporters. Eur J Biochem 219: 713-725, 1994.
32. Younes M, Lechago LV, Somoano JR, Mosharaf M and Lechago J: Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 56: 1164-1167, 1996.
33. Roh MS, Jeong JS, Kim YH, Kim MC and Hong SH: Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas. Hepatogastroenterology 51: 1315-1318, 2004.
34. Bode BP, Fuchs BC, Hurley BP, et al: Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol Gastrointest Liver Physiol 283: G1062-G1073, 2002.
35. Wong MS, Raab RM, Rigoutsos I, Staphanopoulos GN and Kelleher JK: Metabolic and transcriptional patterns accompanying glutamine depletion and repletion in mouse hepatoma cells: a model for physiological regulatory networks. Physiol Genomics 16: 247-255, 2004.
36. Hansson PK, Asztely AK, Clapham JC and Schreyer SA: Glucose and fatty acid metabolism in McA-RH7777 hepatoma cells vs. rat primary hepatocytes: responsiveness to nutrient availability. Biochim Biophys Acta 1684: 54-62, 2004.
37. Thorens B: Molecular and cellular physiology of GLUT-2, a high-Km facilitated diffusion glucose transporter. Int Rev Cytol 137: 209-238, 1992.
38. Wang C and Brennan WA Jr: Rat skeletal muscle, liver and brain have different fetal and adult forms of the glucose transporter. Biochim Biophys Acta 946: 11-18, 1988.
39. Grobholz R, Hacker HJ, Thorens B and Bannasch P: Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis. Cancer Res 53: 4204-4211, 1993.
40. Wilson JE: Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206: 2049-2057, 2003.
41. Goel A, Mathupala SP and Pedersen PL: Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 278: 15333-15340, 2003.
42. Mathupala SP, Rempel A and Pedersen PL: Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29: 339-343, 1997.
43. Rempel A, Mathupala SP and Perdersen PL: Glucose catabolism in cancer cells: regulation of the Type II hexokinase promoter by glucose and cyclic AMP. FEBS Lett 385: 233-237, 1996.
44. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN and Wolf AP: Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19: 1154-1161, 1978.
45. Nelson CA, Wang JQ, Leav I and Crane PD: The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 23: 533-541, 1996.
46. Pasten I and Gottesman M: Multiple-drug resistance in human cancer. N Engl J Med 316: 1388-1393, 1987.
47. Isshiki K, Nakao A, Ito M, Hamaguchi M and Takagi H: P-glycoprotein expression in hepatocellular carcinoma. J Surg Oncol 52: 21-25, 1993.
48. Soini Y, Virkajarvi N, Raunio H and Paakko P: Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 49: 470-473, 1996.
49. Chou YY, Cheng AL and Hsu HC: Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 13: 569-575, 1997.
50. Ng IO, Liu CL, Fan ST and Ng M: Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 113: 355-363, 2000.
51. Lorke DE, Kruger M, Buchert R, Bohuslavizki H, Clausen M and Schumacher U: In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. J Nucl Med 42: 646-654, 2001.
52. Bentley J, Quinn DM, Pitman RS, Warr JR and Kellett GL: The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation. Cancer Lett 115: 221-227, 1997.
53. Yamada K, Brink I and Engelhardt R: Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) accumulation in melanoma cells: is FDG a substrate of multidrug resistance (MDR)? J Dermatol 32: 335-345, 2005.